


## IN THE CLAIMS

### 1. (original) Compounds of formula (I), (Ia) and (Ib)



Wherein:

A is selected from C-X and N,

B is selected from C-Y and N,

R<sup>1</sup> is selected from H and (C<sub>1</sub>-C<sub>6</sub>)alkyl,

R<sup>2</sup> is selected from H and (C<sub>1</sub>-C<sub>6</sub>)alkyl,

X is selected from H, HO, C(O)NH<sub>2</sub>, NH<sub>2</sub>

Y is selected from H, HO, NH<sub>2</sub>, Br, Cl and F

Z is selected from H, HO, F, CONH<sub>2</sub> and CN;

And pharmaceutically acceptable salts, solvates and prodrugs thereof;

With the provisos that:

for a compound of formula (I), (Ia) or (Ib), when A is C-X, B is C-Y, R<sup>1</sup> is H or (C<sub>1</sub>-C<sub>6</sub>)alkyl and R<sup>2</sup> is H or (C<sub>1</sub>-C<sub>6</sub>)alkyl at least one of X, Y and Z must be OH;

for a compound of formula (I), when A is C-X and B is C-Y, Y is H, Z is H, R<sup>1</sup> is H and R<sup>2</sup> is H, then X cannot be OH.

### 2. (Original) Compounds of formula (I), (Ia) and (Ib) as claimed in claim 1 wherein A is C-X or N and B is C-Y.

3. (Currently Amended) Compounds of formula (I), (Ia) and (Ib) as claimed in claims 1-2 1 or 2 wherein R<sup>1</sup> is H, methyl and ethyl.

4. (Currently Amended) Compounds of formula (I), (Ia) and (Ib) as claimed in claims 1-3 1 or 2 wherein R<sup>2</sup> is selected from H and methyl.

5. (Currently Amended) Compounds of formula (I), (Ia) and (Ib) as claimed in claims 1 or 2 1-4 wherein X is selected from H, OH and NH<sub>2</sub>.

6. (Currently Amended) Compounds of formula (I), (Ia) and (Ib) as claimed in claims 1 or 2 1-5 wherein Y is selected from H, NH<sub>2</sub>, Cl and F.

7. (Currently Amended) Compounds of formula (I), (Ia) and (Ib) as claimed in claims 1 or 2 1-6 wherein Z is selected from H, HO and F.

8. (Currently Amended) A compound selected from

R-(-)-3-(4-Propylmorpholin-2-yl)phenol

S-(+)-3-(4-Propylmorpholin-2-yl)phenol

R-(-)-3-(4-Propylmorpholin-2-yl)phenol hydrochloride

R-5-(4-Propylmorpholin-2-yl)benzene-1, 3-diol

S-5-(4-Propylmorpholin-2-yl)benzene-1, 3-diol

R-(+)-2-Fluoro-5-(4-propylmorpholin-2-yl)phenol

S-(-)-2-Fluoro-5-(4-propylmorpholin-2-yl)phenol

5-(4-Propylmorpholin-2-yl)pyridin-2-ylamine

2-Chloro-5-(4-propyl-morpholin-2-yl)phenol

5-[(2*S*,5*S*)-5-methyl-4-propylmorpholin-2-yl]pyridin-2-amine and

5-[(2*R*,5*S*)-5-methyl-4-propylmorpholin-2-yl]pyridin-2-amine.

9. (Cancel)

10. (Currently Amended) A method of treating ~~The use of compounds of formula (I), (Ia) and (Ib) as claimed in claims 1-8 in the preparation of a medicament for the treatment of a condition selected from: sexual dysfunction, female sexual dysfunction, including hypoactive sexual desire disorder, sexual arousal disorder, orgasmic disorder and sexual pain disorder; male erectile dysfunction, hypertension, neurodegeneration, psychiatric disorders, depression (e.g. depression in cancer patients, depression in Parkinson's patients, postmyocardial infarction depression, subsyndromal symptomatic depression, depression in infertile women, paediatric depression, major depression, single episode depression, recurrent depression, child abuse induced depression, post~~

## BEST AVAILABLE COPY

~~partum depression and grumpy old man syndrome~~), generalized anxiety disorder, phobias (~~e.g. agoraphobia, social phobia and simple phobias~~), posttraumatic stress syndrome, avoidant personality disorder, premature ejaculation, eating disorders (~~e.g. anorexia nervosa and bulimia nervosa~~), obesity, chemical dependencies (~~e.g. addictions to alcohol, cocaine, heroin, phenobarbital, nicotine and benzodiazepines~~), cluster headache, migraine, pain, Alzheimer's disease, obsessive-compulsive disorder, panic disorder, memory disorders (~~e.g. dementia, amnesic disorders, and age-related cognitive decline (ARCD)~~), Parkinson's diseases (~~e.g. dementia in Parkinson's disease, neuroleptic-induced parkinsonism and tardive dyskinesias~~), endocrine disorders (~~e.g. hyperprolactinaemia~~), vasospasm (~~particularly in the cerebral vasculature~~), cerebellar ataxia, gastrointestinal tract disorders (~~involving changes in motility and secretion~~), negative symptoms of schizophrenia, premenstrual syndrome, fibromyalgia syndrome, stress incontinence, Tourette's syndrome, trichotillomania, kleptomania, male impotence, attention deficit hyperactivity disorder (ADHD), chronic paroxysmal hemicrania, headache (associated with vascular disorders), emotional lability, pathological crying, sleeping disorder (~~cataplexy~~) and shock comprising administering a therapeutically effective amount of a compound as claimed in claims 1 or 8 to a patient in need of treatment thereof.

11. (Currently Amended) A method as recited in ~~The use as claimed in~~ claim 10 where the condition is female sexual dysfunction, male erectile dysfunction, neurodegeneration, depression and psychiatric disorders.

12. (Currently Amended) A method as recited in ~~The use as claimed in~~ claim 10 where the condition is male erectile dysfunction

13. (Currently Amended) A method as recited in ~~The use as claimed in~~ claim 10 where the condition is hypoactive sexual desire disorder, sexual arousal disorder, orgasmic disorder and sexual pain disorder in females.

14. (Currently Amended) A method as recited in ~~The use as claimed in~~ claim 13 where the condition is female sexual arousal disorder and concomitant hypoactive sexual desire disorder.

15. (Currently Amended) A composition containing a compound of formula (I), (Ia) or (Ib) as ~~claimed~~ recited in ~~claims 1-8~~ claim 1 or 8 and a pharmaceutically acceptable diluent or carrier.